Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Acquiring an injectable GLP-1 drug would not be in Pfizer's interest because "probably it's a little bit too late," Bourla said, referring to Wegovy and Zepbound's class of treatments that target ...

Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan ...

Through the drug, Pfizer aims to offer patients a more convenient alternative to injectable drugs — Eli Lilly's Zepbound and Novo Nordisk's — that currently dominate the weight-loss treatment ...